<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674567</url>
  </required_header>
  <id_info>
    <org_study_id>FLX475-02</org_study_id>
    <secondary_id>KEYNOTE MK3475-PN877</secondary_id>
    <nct_id>NCT03674567</nct_id>
  </id_info>
  <brief_title>Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab</brief_title>
  <official_title>Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAPT Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAPT Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort
      expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as
      monotherapy and in combination with pembrolizumab.

      The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort
      expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential
      cohorts treated with successively higher doses of FLX475 as monotherapy or in combination
      with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of
      parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of FLX475 as a single agent and in combination with pembrolizumab measured by the incidence of adverse events, including dose-limiting toxicities and maximum tolerated dose</measure>
    <time_frame>Approximately 18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate in subjects treated with FLX475 as a single agent and in combination with pembrolizumab</measure>
    <time_frame>Through study completion (approximately 2 years)</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1a: Monotherapy Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b: Combination Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 in combination with pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2a: Monotherapy Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy; additional subjects in each cohort may be enrolled in Stage 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2b: Combination Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 in combination with pembrolizumab; additional subjects in each cohort may be enrolled in Stage 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLX475</intervention_name>
    <description>tablet</description>
    <arm_group_label>Part 1a: Monotherapy Dose Escalation</arm_group_label>
    <arm_group_label>Part 1b: Combination Dose Escalation</arm_group_label>
    <arm_group_label>Part 2a: Monotherapy Expansion Cohorts</arm_group_label>
    <arm_group_label>Part 2b: Combination Expansion Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part 1b: Combination Dose Escalation</arm_group_label>
    <arm_group_label>Part 2b: Combination Expansion Cohorts</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented advanced or metastatic cancer ineligible for standard therapies with one of
             the following histologies

               -  Dose Escalation: non-small cell lung cancer, head and neck squamous cell
                  carcinoma, nasopharyngeal carcinoma, metastatic triple negative breast cancer,
                  urothelial carcinoma, gastric cancer, esophageal carcinoma, cervical cancer,
                  classical Hodgkin lymphoma

               -  Dose Expansion: nasopharyngeal carcinoma, gastric cancer, EBV+ lymphoma, head and
                  neck squamous cell carcinoma, cervical cancer, non-small cell lung cancer,
                  triple-negative breast cancer

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  Evaluable disease at baseline (at least one measurable target lesion by imaging for
             expansion cohorts)

          -  Tumor available for biopsy

        Exclusion Criteria:

          -  History of allergy or severe hypersensitivity to biologic agents

          -  History of Grade 3-4 immune-related adverse events leading to discontinuation of prior
             immuno-oncology treatment

          -  Active autoimmune disease or serious autoimmune disease within past 2 years requiring
             systemic therapy

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, (non-infectious) pneumonitis that required
             steroids, or symptoms of active pneumonitis

          -  Prior allogeneic hematopoietic stem cell transplant within 5 years, or prior
             allogeneic organ transplant

          -  Active graft-versus-host disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Ho, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RAPT Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>650-489-9000</phone>
    <email>clinical.trials@rapt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Archer</last_name>
      <phone>480-256-5168</phone>
      <email>BMDACCResearch@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles JCCC Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashlee Astacio</last_name>
      <phone>310-794-3883</phone>
      <email>AAstacio@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Hotchkins</last_name>
      <phone>203-737-5228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown - Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wagner, RN</last_name>
      <phone>202-687-9782</phone>
      <email>sw1095@georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Hematology and Oncology, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gouri Deshpande</last_name>
      <phone>727-344-6569</phone>
      <phone_ext>1025</phone_ext>
      <email>gdeshpande@flhemonc.com</email>
    </contact>
    <contact_backup>
      <last_name>Gina Askar</last_name>
      <phone>(727)344-6569</phone>
      <phone_ext>1025</phone_ext>
      <email>gaskar@flhemonc.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neron Lewis</last_name>
      <phone>813-745-5247</phone>
      <email>neron.lewis@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chavon Porter</last_name>
      <phone>404-727-3547</phone>
      <email>chavon.porter@emoryhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Janisch, RN</last_name>
      <phone>773-702-1612</phone>
      <email>ljanisch@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital/James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Redman, MD</last_name>
      <phone>502-562-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Scardina, RN</last_name>
      <phone>443-287-6456</phone>
      <email>ascardi2@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DFCI Clinical Trials Hotline</last_name>
      <phone>1-877-DF-TRIAL</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>The Cancer Center Hotline</last_name>
      <phone>800-865-1125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quantum Santa Fe</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chimela Ohaji</last_name>
      <phone>505-913-8935</phone>
      <email>chimela.ohaji@stvin.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Olmos, RN</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley A McClain</last_name>
      <phone>704-947-6599</phone>
      <phone_ext>117</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Referral Office</last_name>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarina Piha-Paul, MD</last_name>
      <phone>713-563-1930</phone>
      <email>spihapau@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Chakar</last_name>
      <phone>61 03 94963088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Bowyer, MD</last_name>
      <phone>+61 (08) 6382 5100</phone>
      <email>Samantha.Bowyer@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>High West</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Wing Yan Chiu</last_name>
      <phone>852-2255 4249</phone>
      <email>jwychiu@hku.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigette Buig Yue Ma</last_name>
      <phone>852-3505 1042</phone>
      <email>Brigette@clo.cuhk.edu.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungbuk</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Hyeong</last_name>
      <phone>82-43-269-6015</phone>
      <email>kihlee@chungbuk.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Min Kim</last_name>
      <phone>82 2 2072 3559</phone>
      <email>tmgabriel7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byoung Chul Cho</last_name>
      <phone>82-10-5212-8867</phone>
      <email>CBC1971@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Bae Kim</last_name>
      <phone>82-2-3010-3217</phone>
      <email>sbkim3@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Joo Min</last_name>
      <phone>82-52-250-8832</phone>
      <email>yjmin65@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu-Chou Su</last_name>
      <phone>+886-6-235 3535</phone>
      <email>sunnysu@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chi Mei Meidcal Center</name>
      <address>
        <city>Tainan</city>
        <zip>71004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin-Hsun Feng</last_name>
      <phone>+886-6-281 2811</phone>
      <email>yinhsun.feng@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Chi Lin</last_name>
      <phone>+886-2-2312 3456</phone>
      <email>cclin1@ntu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muh-Hwa Yang</last_name>
      <phone>+886-2-2875 7270</phone>
      <email>mhyang2@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Chulaongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virote Sriuranpong</last_name>
      <phone>668 6758 5502</phone>
      <email>virote.s@chula.ac.th</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuttapong Ngamphaiboon</last_name>
      <phone>668 4029 2822</phone>
      <email>nuttapong.nga@mahidol.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Urothelial Carcinoma</keyword>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

